Published in Clin Pharmacol Ther on May 01, 1989
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol (1991) 1.54
Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin Pharmacokinet (1995) 1.08
Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol (1999) 1.00
Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol (1991) 1.00
Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol (1990) 0.97
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol (2005) 0.95
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol (1998) 0.95
Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol (1994) 0.93
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol (2001) 0.92
Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br J Clin Pharmacol (1989) 0.92
Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol (1993) 0.87
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol (1999) 0.84
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. Br J Clin Pharmacol (1995) 0.81
Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br J Clin Pharmacol (1999) 0.80
The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. Drug Metab Dispos (2015) 0.80
The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. Br J Clin Pharmacol (1993) 0.79
S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population. Br J Clin Pharmacol (1994) 0.78
Non-linear fluvoxamine disposition. Br J Clin Pharmacol (1998) 0.78
Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events. Br J Clin Pharmacol (2001) 0.76
Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease. Br J Clin Pharmacol (1990) 0.76
CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Ann Rheum Dis (1999) 0.75
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther (1998) 1.72
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis (2008) 1.69
Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet (1986) 1.63
Debrisoquine hydroxylation polymorphism and personality. Lancet (1989) 1.62
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem (2001) 1.57
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry (1981) 1.52
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit (1990) 1.50
Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther (1993) 1.46
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet (1978) 1.42
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37
Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther (2008) 1.29
Diuretic effect and diuretic efficiency after intravenous dosage of frusemide. Br J Clin Pharmacol (1990) 1.29
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol (1995) 1.28
Indole-3-acetic acid in human cerebrospinal fluid: identification and quantification by mass fragmentography. Science (1972) 1.27
Methylation of mercury compounds by methylcobalamin. Biochemistry (1971) 1.27
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol (1996) 1.26
"Serotonin depression"--a biochemical subgroup within the affective disorders? Science (1976) 1.24
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol (1975) 1.20
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol (1987) 1.20
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics (1995) 1.20
Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther (1989) 1.17
Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics (1993) 1.16
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 1.16
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther (2011) 1.15
Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet (1981) 1.14
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis (2004) 1.14
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther (1998) 1.12
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol (1989) 1.12
Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther (1998) 1.11
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol (1994) 1.11
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol (1989) 1.11
The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol (1983) 1.11
High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics (1999) 1.09
Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer (1999) 1.08
Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther (1998) 1.08
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit (1994) 1.05
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry (1995) 1.05
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther (2007) 1.05
The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol (1997) 1.05
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther (1997) 1.03
Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clin Pharmacol Ther (1973) 1.03
Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet (1985) 1.03
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther (1989) 1.02
Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther (1983) 1.01
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther (1996) 1.00
Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther (1997) 1.00
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur J Clin Pharmacol (2008) 1.00
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit (1992) 1.00
Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand (1993) 0.99
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics (1996) 0.99
Valpromide/carbamazepine and risk of teratogenicity. Lancet (1985) 0.99
Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol (1984) 0.99
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol (1986) 0.98
Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci (1979) 0.97
Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther (1980) 0.97
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J (2012) 0.96
Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand (1991) 0.96
Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) (1996) 0.96
Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects. Clin Pharmacol Ther (1984) 0.96
Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. Life Sci (1984) 0.95
CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav (1994) 0.95
Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit (1985) 0.95
Mass fragmentographic quantitation of glutamic acid and gamma-aminobutyric acid in cerebellar nuclei and sympathetic ganglia of rats. J Chromatogr (1976) 0.94
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics (1995) 0.94
Homicide, suicide and CSF 5-HIAA. Acta Psychiatr Scand (1985) 0.94
Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol (1994) 0.93
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics (1996) 0.93
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther (2001) 0.93
Quality of chloroquine preparations marketed in Dar es Salaam, Tanzania. Lancet (1995) 0.93
Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation. J Clin Pharmacol (1986) 0.92
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther (1998) 0.92
Maternal perinatal diet induces developmental programming of bone architecture. J Endocrinol (2013) 0.91
Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol (1991) 0.91
A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics (1992) 0.91
Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry (1980) 0.91
The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther (1999) 0.91
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics (1999) 0.91